MedTrace Logo

"Mechanisms and Biomarkers of Response and Resistance to Current Targeted Therapies in Gastric Cancer" (THERRES)

NCT05051423 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-09-30

No results posted yet for this study

Summary

The main aim was to assess the tumor vascular perfusion pattern in gastric cancer (GC). The investigators used dynamic contrast harmonic imaging endoscopic ultrasound (CHI-EUS) and the results were compared with the immunohistochemical expression of CD105 and clinico-pathological parameters.

Conditions

Interventions

DIAGNOSTIC_TEST

Endoscopic ultrasound

Imaging tests: All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis. CEH-EUS procedure: A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis Molecular tests: Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution. Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes.

Sponsors & Collaborators

  • Institutul Clinic Fundeni

    collaborator OTHER

  • University of Medicine and Pharmacy Craiova

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • Romania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05051423 on ClinicalTrials.gov